Immune checkpoint inhibitors (ICIs) are considered a new standard-of-care across many
cancer indications. This review provides an update on ICIs approved by the Food and Drug …

Sarcomas are a group of diverse and complex cancers of mesenchymal origin that remains
poorly understood. Recent developments in cancer immunotherapy have demonstrated a …

The role of immunotherapy in bladder urothelial cancers is rapidly expanding. Since the
initial second-line therapy approval for patients who fail prior platinum-based chemotherapy …

Aim This review article summarizes the current clinical practice guidelines around disease
definitions and risk stratifications, and the treatment of non-muscle-invasive bladder cancer …

Simple Summary Urothelial bladder cancer (BC) is one of the most fatal cancers, with a
dismal five-year survival rate of 5% in patients with metastatic disease. Clinically relevant …

Bladder cancer is the 10th most common cancer type in the world. There were more than
573,000 new cases of bladder cancer in 2020. It is the 13th most common cause of cancer …

For nearly 50 years, immunotherapy has been used in patients with bladder cancer in the
form of Mycobacterium bovis Bacillus Calmette-Guerin (BCG), which is still the first-line …

Abstract Purpose of Review The treatment options for high-risk non-muscle invasive bladder
cancer (NMIBC), particularly following BCG, remain limited. We highlight recent, promising …

Introduction Since 2016, the progressive use of immune checkpoint inhibitors (ICIs) starting
from second-line treatment has led to an improvement in overall survival in locally advanced …

Purpose: Recurrent disease after bacillus Calmette-Guérin treatment presents a therapeutic
challenge. To aid trial development, the US Food and Drug Administration defined …